This is evident since systemic administration of CAY10444, an S1PR3 antagonist, suppressed expression of angiogenic growth factors and neovascularization of a neoplasm in a mouse ovarian cancer model [33]. This evidence concerns the gene S1PR3 and ovarian cancer.